FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Neuronal Repair in MS May Be Triggered by an Inflammatory Molecule






































CXCL12 found to drive re-myelination and neurogenesis during spontaneous remission in EAE mice

A new study from The Weizmann Institute of Science, Israel, found that the inflammatory molecule CXCL12 promotes neuronal repair during spontaneous remission in mice with experimental autoimmune encephalomyelitis (EAE), an animal model of human multiple sclerosis (MS).

The chemokine CXCL12 was previously thought to be a pro-inflammatory molecule only. But recent findings have shown that — depending on interactions with other factors, as well as the interactions’ timing and context — CXCL12 could also be anti-inflammatory and immunomodulating, and promote re-myelination.

The research team induced EAE in the mice and tracked the expression of CXCL12 in their brains, both during disease development and in the period of spontaneous remission. Researchers observed that levels of the molecule increased steadily while the disease advanced, and did not subside when the mice spontaneously recovered. Instead, the team found that the levels of the immune factor increased even further, even though inflammation was no longer present in the brain. The levels of CXCL12 in mice recovering from EAE were found to be significantly higher than in mice that had not experienced inflammation.

The spontaneous remission process was also accompanied by increased numbers of two cell types destined to turn into either new neurons or oligodendrocyte cells. Oligodendrocytes are the main myelin producing cells in the brain. A closer investigation of these cells showed that they were a source of CXCL12 and its receptor CXCR4.

The results highlighted the complexity of the immune response, showing that increased levels of immune molecules do not always contribute to pathology, but might be elevated to protect tissue, or — as in this case — triggering re-myelination and neuronal repair following inflammation.

The findings offer an important insight into healing processes in the brain, which might be explored in further studies aiming to develop new MS treatments.

The study, “Post-CNS-inflammation expression of CXCL12 promotes the endogenous myelin/neuronal repair capacity following spontaneous recovery from multiple sclerosis-like disease,” was led by Rina Zilkha-Falb from Sheba Medical Center and colleagues from The Weizmann Institute of Science, both in Israel, and the Ludwig-Maximilians-University, Munich, Germany. It was published online in the Journal of Neuroinflammation.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News